Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutininLarry Smith, Ronald B. Moss, Souphaphone Boutsaboualoy et al.|Vaccine|2010Cited by 142
Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe VaccinationRobert L. Atmar, John J. Treanor, Frank Baehner et al.|The Journal of Infectious Diseases|2019Cited by 30